
PathAI, an artificial intelligence (AI) pathology solutions provider, has launched the PathAssist Derm tool that orients, identifies, and measures skin lesions.
Available now on the AISight Image Management System (IMS), PathAssist Derm helps identify skin lesions based on specimen entities.
It speeds up the skin lesion review process, improving dermatopathology research workflows.
PathAssist Derm helps assess skin specimens by automating specimen orientation. It eliminates the need for manual glass slide orientation.
The tool can predict 17 entities, including common ones like actinic keratoses and basal cell carcinomas, as well as rare conditions like lichenoid keratoses and melanomas. It also provides precise lesion measurements.
PathAssist Derm enhances H&E slide analysis. It also empowers researchers to accelerate progress in skin cancer research.
The pathology solutions provider is collaborating with several laboratories to explore efficiency improvements.
PathAI co-founder & CEO Andrew Beck said: “Skin cancer remains the most prevalent cancer worldwide, with over 1.5 million new cases diagnosed annually, which are associated with 60,000 deaths from melanoma alone.
“These statistics present a critical opportunity for innovation in skin cancer research, both in the diagnostic and therapeutic realms.
“Our goal with PathAssist Derm is to provide researchers with a scalable tool that enhances dermatopathology research through AI-enabled lesion characterisation and workflow efficiency, as part of our overall vision to improve patient outcomes with AI-powered pathology.”
PathAssist Derm is PathAI’s first AI product offering broad dermatopathology characterisation. It also expands the AI-powered solutions available on the AISight IMS.
As the AISight Image Management System grows, pathologists gain more tools to streamline workflows, enhance efficiency, and reduce time spent on manual tasks, PathAI said.
With each new advancement, pathologists are better equipped to deliver precise, actionable insights for diagnostic research.
AISight is a cloud-native, intelligent enterprise solution designed to enhance digital pathology workflows.
Its browser-accessible, cloud-based architecture ensures rapid activation and scalability without extra infrastructure costs.
Built for pathologists, AISight includes image analysis and collaboration tools for an intuitive user experience.
The platform also features an open AI environment, incorporating AI algorithms from PathAI and third-party partners for various histopathology applications.
In October 2024, Clario entered a partnership with PathAI to offer an integrated solution for gastrointestinal (GI) clinical trials.